Sofosbuvir Withdrawn Phase 4 Trials for Hepatitis C Virus (HCV) Infection Treatment

WithdrawnTreatment4 IdentifierTitleDrugs
NCT03105349A Clinical Trial of 16 Weeks of Duration to Evaluate Retreatment With Elbasvir/Grazoprevir Plus Sofosbuvir and Ribavirin in Patients With Chronic Hepatitis C Genotypes 1,4 Who Have Failed to Treat With a Regime Based on an Inhibitor of the NS5A